Abstract
Current treatments for central nervous system (CNS) inflammatory demyelinating diseases (IDDs) include corticosteroids, plasma exchange, intravenous immunoglobulin, and immunosuppressant drugs. However, some patients do not respond well to traditional therapies. In recent years, novel drugs, such as monoclonal antibodies, targeting the complement component C5, CD19 on B cells, and the interleukin-6 (IL-6) receptor, have been used for the treatment of patients with refractory CNS IDDs. Among these, tocilizumab and satralizumab, humanized monoclonal antibodies against the IL-6 receptor, have shown beneficial effects in the treatment of this group of diseases. In this review, we summarize current research progress and prospects relating to anti-IL-6 therapies in CNS IDDs.
Funder
National Natural Science Foundation of China
Subject
Immunology,Immunology and Allergy
Reference92 articles.
1. Myelin oligodendrocyte glycoprotein antibodies in neurological disease;Reindl;Nat Rev Neurol,2019
2. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases;Mader;Curr Opin Neurol,2020
3. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS;Kim;Neurol Neuroimmunol Neuroinflamm.,2015
4. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients part 1: Frequency, syndrome specifcity, infuence of disease activity, long-term course, association with AQP4-IgG, and origin;Jarius;J Neuroinfammation.,2016
5. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody;Höftberger;Acta Neuropathol.,2020
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献